Introduction
============

The hypothalamo-pituitary--adrenal (HPA) axis represents a complex series of neural signals that ultimately controls the hormonal response to stressors. Stress, as originally defined by Hans Selye ([@B101]) is "...the non-specific response of the body to any demand for change...." Thus, the HPA axis represents one of several "non-specific" response systems that are used by the brain to adjust multiple physiological functions in an attempt to maintain homeostasis. Other "non-specific" responses activated by stressors may include the immune system and autonomic nervous system. Although stress may have positive (eustress) or negative (distress) connotations, the consequences of unresolved persistent stress responses can lead to severe neuropsychiatric disorders in susceptible individuals (Selye, [@B102]).

Regulation of the HPA axis by gonadal steroid hormones is an important consideration in anxiety and affective disorders. For example, major depressive disorder (MDD), and anxiety disorders, are current major public health concerns and are responsible for substantial social and economic burden in developed countries (Murray and Lopez, [@B70]; Ustun et al., [@B114]). Of interest, women are up to 2.5 times more likely than men to be diagnosed with MDD in their lifetime (Fava and Kendler, [@B26]; Kessler, [@B46]), and women have a significantly higher heritability of MDD than men (Kendler, [@B45]; Hettema et al., [@B37]). Clinical studies of depressed patients reveal that the sex differences in incidence arise at adolescence and more closely coincide with androgen and estrogen levels rather than physical changes associated with puberty (Warren and Brooks-Gunn, [@B126]; Angold and Worthman, [@B7]; Angold et al., [@B6]). As a result, changing patterns of hormones and hormone sensitivity may be implicated as potential etiological factors. In this review, we explore the steroid hormone influences on the regulation of HPA axis function that could influence susceptibility to disease states such as affective disorders, with particular emphasis on androgens and estrogenic metabolites of androgen.

The Hypothalamo-Pituitary--Adrenal Axis
=======================================

Glucocorticoid hormones, the end-product of the HPA axis, are secreted by the adrenal cortex into the general circulation, under tight hypothalamic control. The HPA axis represents a cascade of neural and humoral signals organized by a central circadian pacemaker and activated in response to environmental triggers. Under non-stressed conditions, the release of corticosterone from the rodent adrenal cortex is linked to a circadian regulatory system (Chung et al., [@B19]). Circulating adrenal glucocorticoid levels are lowest during the inactive phase (light period in rodents, dark period in humans) and begin to rise several hours preceding the onset of activity or awakening (L:D transition in rodents) to peak shortly after activity onset. Thus, the rise in adrenal glucocorticoid secretion predicts and readies physiological systems for the onset of activity and feeding (Nader et al., [@B71]). The diurnal rise in glucocorticoids is allowed to occur by decreases in vasopressin (AVP) from the SCN that normally inhibit neurons in the paraventricular nucleus (PVN; Szafarczyk et al., [@B113]; Kalsbeek et al., [@B43]; Caldwell et al., [@B16]). Moreover, adrenal sensitivity to adrenocorticotropic hormone (ACTH) changes over the day thereby altering the corticosterone response to ACTH in a diurnal fashion (Oster et al., [@B79]).

In addition to diurnal signals regulating adrenal glucocorticoid secretion, changing environmental conditions or perceived threats to homeostasis activate the HPA through a common final pathway involving neurons located in the medial parvocellular division of the PVN of the hypothalamus. These neurons integrate excitatory and inhibitory inputs received from multiple brain areas (Cullinan et al., [@B21]; Herman et al., [@B36]; Choi et al., [@B17]). Thus, the motor neurons driving the HPA response to stress are neuroendocrine neurons that contain corticotrophin-releasing hormone (CRH) and that project to the median eminence. The release of CRH into the hypothalamo-hypophyseal portal system stimulates the release of ACTH from the anterior pituitary gland by acting upon the CRH-R1 receptor on corticotrophs (Aguilera et al., [@B4]).

Several additional neuropeptide phenotypes make up the PVN neurons that control HPA axis activity. Vasopressin and oxytocin are found at high levels in magnocellular and parvocellular neurons of the PVN. Although typically thought to regulate osmotic balance and parturition, vasopressin, and oxytocin have been shown to co-localize with CRH in discrete PVN populations and to be co-released with CRH (Whitnall, [@B132]; Bondy et al., [@B13]; Raadsheer et al., [@B87]). Vasopressin reportedly acts synergistically with CRH to potentiate CRH's secretogogue activity at the level of the corticotroph (Rivier and Vale, [@B91]; Schlosser et al., [@B99]; Papadimitriou and Priftis, [@B82]), whereas a role for the oxytocin in CRH neurons has not been determined (Palkovits, [@B80]). Nonetheless, both vasopressin and oxytocin can stimulate ACTH secretion even in the absence of CRH (Gillies et al., [@B31]). In contrast, when applied to the PVN, or injected into the third ventricle, oxytocin inhibits HPA responses (Windle et al., [@B135]; Neumann et al., [@B75]) suggesting the possibility that oxytocin can be released locally from PVN neurons, perhaps through dendritic release (Landgraf and Neumann, [@B56]; Neumann, [@B74]).

Following the release from corticotrophs of the anterior pituitary, ACTH acts on the adrenal cortex to stimulate the synthesis and secretion of CORT. Circulating CORT has numerous effects throughout the body, one of which is to signal to the anterior pituitary, hypothalamus, and higher brain areas to limit further hormone secretion (Gomez et al., [@B32]) thus closing this neuroendocrine negative feedback loop.

Roles for Gonadal Steroids in Regulating the HPA Axis
=====================================================

Androgens and androgen receptors
--------------------------------

Although testosterone and estradiol are classic reproductive hormones, both have been reported to regulate the HPA axis (Gaskin and Kitay, [@B29], [@B30]; Coyne and Kitay, [@B20]). Gonadectomy of male rats increases corticosterone and ACTH responses to stress and correspondingly, c-fos mRNA expression in the PVN is elevated (Handa et al., [@B34]; Viau et al., [@B119]; Lund et al., [@B61],[@B62]). The effects of testosterone (T) are not through aromatization to estradiol given that hormone replacement of castrated rats with the non-aromatizable androgen, dihydrotestosterone (DHT) returns stress-responsive plasma CORT, and ACTH levels back to that of the intact male. Hormone replacement also inhibits the stress-induction of c-fos mRNA in the PVN (Viau, [@B117]; Viau et al., [@B119]; Lund et al., [@B62], [@B60]). Additional evidence for an androgenic regulation of HPA axis reactivity comes from studies examining the hormonal stress response of male rats before and after puberty. Prior to puberty, when T levels are low, the CORT response to acute and chronic stress is high relative to the response seen after puberty (Viau et al., [@B118]; Romeo and McEwen, [@B92]; Follib et al., [@B27]). This correlates with the increases in T that occur during the pubertal transition of males. However, given that Romeo et al. ([@B93]) have shown that T administration cannot shift the pattern of HPA regulation in pre-pubertal males to that of post-pubertal males, the involvement of T is not sufficient for the pre- and post-pubertal changes observed in HPA axis activity.

Androgens have been reported to inhibit HPA axis function (Handa et al., [@B34]) and alter CRH-immunoreactivity (ir; Bingaman et al., [@B10]) and vasopressin mRNA within the PVN (Viau et al., [@B123]). Nonetheless, androgen receptors (AR) are not localized in hypophysiotrophic CRH or AVP neurons within the PVN (Bingaman et al., [@B11]) and have only been reported in the dorsal and the ventral medial parvocellular parts of the PVN, which are non-neuroendocrine neurons that project to spinal cord and brainstem pre-autonomic nuclei (Bingham et al., [@B12]). Consequently, it has been hypothesized that androgens regulate PVN neuropeptide expression and secretion trans-synaptically. Data supporting this hypothesis come from studies showing that AR are in neurons projecting to the PVN (Williamson and Viau, [@B134]) and that the implantation of testosterone into the medial preoptic nucleus (MPN) and bed nucleus of the stria terminalis (BnST), brain regions that provide afferent input to the PVN, can reduce the CORT response to acute stress (Viau and Meaney, [@B121]). Testosterone micro-implants to the MPN of gonadectomized rats can also decrease stress-induced expression of c-Fos in the PVN and lateral septum, an effect that is blocked by lesions of the MPN (Williamson et al., [@B133]). Further, retrograde tracing studies show that AR-ir can be found in neurons of the BnST, but not the septum, that project to the PVN (Suzuki et al., [@B112]). However, the MPN/BnST are likely not the only brain site(s) mediating androgen's inhibitory effect on HPA reactivity given that stereotaxic application of DHT to a region just above the PVN (to prevent mechanical disruption of the PVN) is also effective in reducing CORT and ACTH responses to stress (Lund et al., [@B60]). We interpret such data as indicating that DHT can also have direct actions on PVN hypophysiotrophic neuron functions. However, based on AR distribution in brain, the local inhibitory action of DHT on PVN neurons likely occurs through a multisynaptic pathway that involves activation/inhibition of several neural pathways and the resulting feedback loops to inhibit activity of neurosecretory PVN neurons. An alternate, but not mutually exclusive possibility is that DHT may act through another receptor type found in the PVN or in neurons projecting to the PVN. Our recent results implicate ER beta (Lund et al., [@B60]), as an important receptor for DHT's actions.

Estrogens and estrogen receptors
--------------------------------

The role of estrogens in regulating stress reactivity remains controversial. Initial studies showing sex differences in corticosterone responses to a stressor (Gaskin and Kitay, [@B29]) demonstrated that sex steroid hormones could interact with the regulatory elements of the HPA axis. Gonadectomy of both males and females reduces the sex difference and hormone replacement to gonadectomized animals can reinstate the sex difference (Handa et al., [@B35]). Initial studies indicated that estradiol treatment enhanced, and testosterone treatment inhibited HPA reactivity (Kitay, [@B47]; Viau and Meaney, [@B120], [@B121]; Burgess and Handa, [@B15]; Handa et al., [@B34]). For estradiol, the direction of effect has not always been consistent, as enhancement (Isgor et al., [@B41]) and inhibition (Orchedalski et al., [@B77]) of HPA activity following estradiol have also been reported. Moreover, evidence is present in the literature showing that estradiol and testosterone can act at the adrenal gland (Kitay, [@B48]), anterior pituitary (Coyne and Kitay, [@B20]; Viau and Meaney, [@B122]), and hypothalamus (Handa et al., [@B34]; Viau and Meaney, [@B121]; Viau et al., [@B119]). Thus, contributions to each level of the axis may mediate the gonadal steroid effects on HPA function. Furthermore, amplitude and duration of hormone exposure could also influence the actions of gonadal steroid hormone effects on HPA axis function (Orchedalski et al., [@B77]).

Following the initial discovery of a second form of estrogen receptor, termed ERbeta (Kuiper et al., [@B52]), its mRNA and immunoreactivity were shown to be highly expressed by PVN neurons (Shughrue et al., [@B104]; Laflamme et al., [@B54]; Shughrue and Merchenthaler, [@B105]; Suzuki and Handa, [@B110]). A large number of ERbeta-ir cells in PVN are OT positive, and ERbeta is also found in AVP and prolactin expressing neurons (Alves et al., [@B5]; Hrabovsky et al., [@B39]; Somponpun and Sladek, [@B107]; Suzuki and Handa, [@B111]). Many fewer CRH neurons of the PVN express ERbeta (Laflamme et al., [@B54]; Suzuki and Handa, [@B111]; Miller et al., [@B69]). These data suggest that by binding to ERbeta, E2 might directly alter the function of PVN neuropeptide neurons. Indeed, the administration of ERbeta agonists to rats cause an inhibition of stress-induced corticosterone secretion (Lund et al., [@B60]; Weiser et al., [@B131]), coupled with increased anxiolytic-like behaviors (Walf et al., [@B124]; Lund et al., [@B63]; Weiser et al., [@B131]). A PVN site of action in the regulation of HPA reactivity has been demonstrated by the studies of Lund et al. ([@B60]) who placed ERbeta agonists in an area adjacent to the PVN and demonstrated a reduction of stress-responsive corticosterone and ACTH secretion in ovariectomized female rats. In contrast, ERalpha agonists had an enhancing effect on corticosterone and ACTH. Little ERalpha is found in the PVN and it does not associate with CRH, AVP, or OXY neurons (Simerly et al., [@B106]; Estacio et al., [@B25]; Suzuki and Handa, [@B111]). Thus, a direct action of E2 that is mediated by ERalpha acting through neuropeptide neurons of the PVN to regulate stress reactivity appears unlikely.

Synthesis and Metabolism of Gonadal Steroid Hormones
====================================================

In all steroid-synthesizing tissues, the conversion of cholesterol to pregnenolone by the side chain cleavage enzyme, P450scc or CYP11A1, is considered to be the rate-limiting step in steroidogenesis and occurs in the mitochondria of steroid-synthesizing cells. Pregnenolone is transported outside the mitochondria for subsequent synthetic steps. The weak androgen, androstenedione is produced via a delta4 pathway that first involves the conversion of pregnenolone to progesterone and then 17alpha hydroxyl progesterone by the enzymes 3β hydroxysteroid dehydrogenase (3β HSD) and 17alpha hydroxylase, respectively. Androstenedione is formed from 17alpha hydroxy-progesterone by 17,20 lyase activity. In humans, the pathway for androgen synthesis largely involves the delta5 pathway that produces dehydroepiandrosterone (DHEA) as the precursor for androstenedione. Depending on the tissue examined, androstenedione can be converted to testosterone by Type 3 17β hydroxysteroid dehydrogenase (17β HSD) or to estrone by the aromatase enzyme. Type 1 17β HSD is responsible for the conversion of estrone to estradiol whereas aromatase can also synthesize estradiol, using testosterone as the precursor (see Figure [1](#F1){ref-type="fig"}A; Rosen and Cedars, [@B94]).

![**Biosynthetic pathway for gonadal steroid hormones**. **(A)** Shows known enzymes and intermediates leading to the synthesis of estrogens and androgens from cholesterol. **(B)** Shows the metabolic steps of dihydrotestosterone processing putatively involved in pre-receptor regulation of ERbeta activation. 3α-Diol = 5α androstane 3α, 17β Diol; 3β Diol = 5α androstane 3β, 17β Diol, RL-HSD = 11-cis-retinol dehydrogenase like 3α-HSD.](fendo-02-00065-g001){#F1}

In brain and other steroid sensitive tissues, there are overlapping functions that have been attributed to androgens and estrogens based on studies showing that the brain is a rich source of aromatase activity and testosterone is a precursor to estradiol in brain (Abdelgadire et al., [@B1]; Naftolin, [@B72]). Testosterone can also be converted to the more potent androgen, DHT, by the 5α reductase enzyme (5αR; Krieger et al., [@B50]; Melcangi et al., [@B68]). For many years, DHT was considered a prototypic androgen receptor (AR) agonist, with greater binding activity at the AR compared to testosterone (Zhou et al., [@B136]). Moreover, unlike testosterone, DHT cannot be aromatized to estradiol-like metabolites. In contrast, recent data indicate that DHT may be converted to products with estrogen-like activity, but by enzymes other than aromatase (Weihua et al., [@B128], [@B129]).

The principal metabolites of DHT are 5α-androstane 3β, 17β Diol (3β-Diol), and 5α- androstane 3α, 17β Diol (3α-Diol). Both steroids have little activity at the AR, however 3β-Diol has a moderate ability to bind and activate ERbeta (Kuiper et al., [@B51]; Weihua et al., [@B128]). 3β-Diol is synthesized from DHT by the actions of multiple enzymes including 3αHSD, 17αHSD, and 3βHSD, whereas 3β Diol is metabolized to 6α- and 7α-triol by the actions of CYP7b1 (Figure [1](#F1){ref-type="fig"}B; Jin and Penning, [@B42]; Gangloff et al., [@B28]; Steckelbroeck et al., [@B108]; Penning et al., [@B85]). In contrast, 3α-Diol is synthesized from DHT through the actions of 3αHSD. This reaction is a reversible reaction through the actions of "RoDH Like" 3αHSD (RL--HSD; Bauman et al., [@B9]). Thus, any of these enzymes may be important in pre-receptor regulation of androgen action. Based on the metabolism of DHT to 3β-Diol, Weihua et al. ([@B128], [@B129]) suggested a role for ERbeta in mediating its actions in prostate gland. Given the important role that estrogens play in regulating the HPA axis, particularly those that bind ERbeta, these DHT metabolites could play an important role in the regulation of non-reproductive functions such as stress reactivity in the rodent.

3β-Diol and the Regulation of the HPA Axis
==========================================

The ability of 3β-Diol to regulate the reactivity of the HPA axis was first described by Lund et al. ([@B61]) who tested the ability of peripherally administered 3β-Diol-diproprionate to alter stress-responsive CORT and ACTH secretion in castrated adult male mice. These studies revealed that 3β-Diol treatment was as effective as DHT in reducing the gain of stress-induced CORT and ACTH secretion. Moreover, the effects of 3β-Diol could be blocked by co-administration of the non-selective ER antagonist, tamoxifen, but not by the AR antagonist, flutamide, thus implicating estrogen receptors in the actions of both DHT and 3β-Diol. Furthermore, ERbeta agonists inhibited HPA reactivity in a fashion similar to DHT and 3β-Diol, whereas ERalpha agonists did not.

Evidence for the PVN being the primary neural target of 3β-Diol's HPA inhibiting activity has also been demonstrated (Lund et al., [@B60]). Using small pellets of beeswax as a carrier for hormone, it was found that the stereotaxic application of 3β-Diol to the PVN of castrated male rats mimicked the actions of both central and peripherally administered DHT. Such local application of the ERbeta agonist, diarylpropionitrile (DPN), could also mimic the actions of DHT. The inhibitory actions of 3β-Diol and DPN were blocked by co-administration of tamoxifen, whereas the AR antagonist, flutamide had little effect. Although it is currently unknown whether 3β-Diol is produced by cells in or near the PVN, the fact that mRNAs for the steroid metabolizing enzymes such as 5αR, 3αHSD, 17αHSD, and CYP7b1 are found in the PVN suggests that local synthesis of the hormone may be responsible (Lund et al., [@B60]). Thus, the paracrine effects of 3β-Diol on nearby cells of the PVN likely impact the function of HPA reactivity to stressors through binding to ERbeta.

3β-Diol has also been shown to impact other neurobiological systems through ERbeta. For example, Osborne et al. ([@B78]) demonstrated that 3β-Diol improved performance in the Morris water maze and Pendergast et al. ([@B84]) demonstrated that 3β-Diol can regulate tyrosine hydroxylase expression in the locus coeruleus.

In contrast to the actions of 3β-Diol-bound ERbeta, estradiol appears to act primarily through ERalpha to augment HPA reactivity. Estradiol and the ERalpha selective agonist, propylpyrazole-triol (PPT), oppose the action of ERbeta agonists and consistently increase HPA reactivity to restraint stress (Lund et al., [@B60]). Given the co-localization of ERalpha in GABAergic neurons in the peri-PVN area, it has been hypothesized that ERalpha increases the gain of the HPA axis through modulation of local inhibitory circuits (Weiser and Handa, [@B130]).

Unknown at present are the mechanisms by which the HPA axis distinguishes enhancing from inhibiting actions of estradiol, a hormone that binds with similar high affinity to both ERalpha and ERbeta (Kuiper et al., [@B51]; Lund et al., [@B63]). It is possible that the ratio of ERalpha to ERbeta or the phenotype of neuron that expresses ERalpha and ERbeta may be altered under different physiological conditions. A greater alpha/beta ratio could cause a shift toward enhanced gain and the opposite would be true under conditions where ERbeta was elevated compared to ERalpha. Indeed, it has been demonstrated that levels of ERbeta change in response both to circulating glucocorticoid and estradiol levels (Isgor et al., [@B41]; Suzuki and Handa, [@B110]). This would allow the gain of the system to shift based on a given physiological state. An alternate hypothesis is that estradiol works predominantly by activating ERalpha, whereas other endogenous ligands, such as 3β-Diol are used to activate ERbeta.

Molecular Mechanism of Regulating CRH, AVP, and OT Expression
=============================================================

The receptors for estradiol (ERalpha and ERbeta) and for DHT (androgen receptor) belong to the nuclear receptor (NR) superfamily of proteins. The NR superfamily is a large group of transcription factors, most of which are ligand-activated. Characteristics of the steroid receptor branch of the family include their ability to interact with three types of response elements: (1) an inverted palindrome, (2) a composite element (Diamond et al., [@B24]), and (3) a "tethering" element (Lefstin and Yamamoto, [@B57]). Inverted palindromes are "classic" elements; they were the first described and for years were thought to be the sole means by which a receptor could interact with DNA to regulate transcription. Composite elements for steroid receptors consist of a hormone response element half-site, and a half-site for a monomer of another transcription factor. In fact, an example of this is the negative glucocorticoid response element in the proximal region of the CRH promoter (Malkoski et al., [@B65]; Malkoski and Dorin, [@B64]). The third type is a tethering or DNA-binding independent element, one in which a transcription factor regulates the activity of another transcription factor bound to its own DNA-binding site. This mechanism is also called an alternate pathway. A well-studied example is ER action mediated through an AP-1 or Sp-1 transcription factor bound to its DNA element (Kushner et al., [@B53]; Safe and Kim, [@B97]). Awareness of these three modes of regulation is critical for understanding ER regulation of CRH, VP, and OT.

3β-diol-regulated CRH expression
--------------------------------

E2 regulated CRH expression was first described by Vamvakopoulos and Chrousos ([@B115]) who analyzed ER binding at estrogen response element (ERE) half-sites. At the time alternate pathways of gene regulation by ERs were only beginning to be explored and ERbeta had yet to be discovered. Thus, given that the CRH promoter is devoid of palindromic EREs, the ERE half-sites were a logical target for analysis.

By 2004, the ability of ER regulation of gene expression *via* alternate pathways was well established, particularly for SP-1 and AP-1 (Kushner et al., [@B53]; Safe and Kim, [@B97]). The cAMP regulatory element binding protein (CREB) binding protein (CBP) had been found to be a co-activator for AP-1, as well as CREB (Bannister et al., [@B8]) and steroid receptor co-activators (SRCs) were known to interact with CBP (reviewed in McKenna et al., [@B67]). Based on these and numerous other data, Kushner et al. ([@B53]) proposed that ER regulation through AP-1 involved formation of an ER:SRC:CBP complex. The fact that CRH activation is critically dependent on the proximal cAMP regulatory element (CRE; Seasholtz et al., [@B100]) suggested that its activation could also be mediated via an alternate pathway, one that was regulated *via* CREB.

The discovery of ERbeta (Kuiper et al., [@B52]) greatly broadened the approach to CRH regulation. Using a widely used CRH promoter:reporter construct (−663 to +124; Seasholtz et al., [@B100]; Guardiola-Diaz et al., [@B33]), Miller et al. ([@B69]) demonstrated that various splice variants of ERbeta activated the CRH promoter activity to different degrees. The most potent isoform was ERbeta 1δ3, which mediated a 12.5 fold increase in CRH promoter activity in the presence of E2. In the presence of Tmx, ERbeta 1, and ERbeta 2δ3 activated the promoter, as well. That an anti-estrogen could activate the promoter corroborated the hypothesis that CRH regulation involves an alternate pathway (Miller et al., [@B69]). This hypothesis was strengthened by examining the occupancy of the endogenous CRH promoter by ERalpha, ERbeta and associated coregulators in a CRH expressing amygdalar cell line (Kasckow et al., [@B44]; Lalmansingh and Uht, [@B55]). Results of chromatin immuno-precipitation analysis followed by quantitative PCR showed that ERalpha and beta occupancy in the region of CRE at the proximal promoter increased by approximately 22- and 12-fold respectively. The peak occupancy was different for the two receptors. ERalpha and beta peaked at 1 and 3 min, respectively. Furthermore, the pattern of ERalpha and beta occupancy correlated differentially with SRC-1 and CBP occupancy, suggesting that ERalpha and beta exist in distinct complexes (Lalmansingh and Uht, [@B55]). The increases in occupancy were tightly correlated with the expression profile of CRH mRNA, suggesting that the ER interactions with the CRH promoter are functional.

More recently, another neuronal cell line that constitutively expresses CRH was used to assess the effect of different estrogenic ligands on CRH promoter activity (Ogura et al., [@B76]). E2 and the ERbeta selective agonist diarylpropionitrile (DPN) increased reporter activity in hypothalamic IVB cells whereas the ERalpha agonist, propylpyrazole-triol (PPT) did not. These data suggest that in certain cellular contexts ERbeta, but not ERalpha, activates the CRH promoter. These data are germane to HPA axis regulation by 3β-Diol, which has been shown to act via ERbeta at the VP promoter (Pak et al., [@B81]).

Direct evidence for the regulation of CRH by 3β-Diol has been reported by Huang et al. ([@B40]). Using CHO-K1 cells, they showed that E2 and 3β-Diol increased CRH promoter activity to the same extent, and did so through both ERalpha and ERbeta. In distinction Tmx reduced the E2 and 3β-Diol induced promoter activity to the level of vehicle in all cases, a finding consistent with an ER-mediated response. More recently, we have found that 3β-Diol treatment stimulates CRH expression rapidly; it increases mRNA levels between 1 and 5 mins of exposure (Stacey and Uht, unpublished data). Thus, emerging evidence demonstrates that 3β-Diol increases CRH expression and likely does so through an alternate pathway of gene regulation.

3β-diol-regulated AVP expression
--------------------------------

Prior to investigating the effects of 3β-Diol in AVP regulation, investigators had evaluated the role of ERalpha and ERbeta in regulating AVP expression. Using reporter assays, the differential regulation of AVP promoter activity by ERalpha and beta was studied (Shapiro et al., [@B103]). These investigators traced ERalpha and beta activity, in the presence of E2, to an upstream ERE, between −5.5 and −4.0 kb and ERbeta repression to a proximal region of the promoter that contains several AP-1 sites.

The effects of 3β-Diol at the AVP promoter, mediated through ERbeta1 and its splice variant, ERbeta2, has also been examined (Pak et al., [@B81]). In a fashion similar to that shown by Shapiro et al. ([@B103]), ERbeta1 displayed constitutive activity in the proximal promoter. Maximal constitutive activity required the region between −740 b and 1.3 kb of the AVP promoter. ERbeta2 also displayed constitutive activity but approximately half of that exhibited by ERbeta1 (Pak et al., [@B81]). In distinction to the studies by Shapiro and colleagues, Pak et al. ([@B81]) did not report that E2 down-regulated the constitutive activity of ERbeta1. Rather, in the presence of ERbeta1, E2 had no effect whereas DHT and 3β-Diol increased activity. In the presence of ERbeta2, however, E2 and 3β-Diol increased activity whereas DHT had no effect. That 3β-Diol increases AVP reporter activity through both ER-beta1 and -beta2 is striking, given that the difference between the two receptors has been traced to the ligand-binding domain. Lastly, Pak et al. ([@B81]) showed that expression of a GRIP/SRC-2-NR box abrogated the 3β-Diol effect through ERbeta1, suggesting that 3β-Diol elicits an AF-2 conformation similar to E2. As the authors suggest, it will be interesting to determine whether the spectrum of co-activators required by 3β-Diol-bound ERbeta1 and ERbeta2 differ. Regardless of which co-activators are used, 3β-Diol clearly regulates AVP expression. Moreover, sufficient information is present in the literature to suggest that 3β-Diol could target AVP expressing neurons in the PVN.

3β-diol-regulated OT expression
-------------------------------

For years, the OT promoter has been known to be estrogen responsive (Richard and Zingg, [@B89]). However, dissection of the molecular mechanisms of OT regulation has been hampered by species differences in the upstream promoter and a complex composite hormone response element within the proximal promoter. A point in common across species is the location of the primary site of estrogen regulation at about −160 bp (Richard and Zingg, [@B89]; Adan et al., [@B3]). The composite response element contains sequences in common with a consensus ERE; however, the degree to which it binds ERalpha and/or beta is species dependent.

Common to all species is the ability of two "orphan" receptors to bind the response element. These are steroidogenic factor-1 (SF-1) and a chicken ovalbumin upstream promoter transcription factor COUP--TF (Wehrenberg et al., [@B127]). The site is also bound by other NRs such as the retinoic acid and thyroid hormone receptors and the orphan receptor ERRα; however, the extent to which they do so is again species dependent (Richard and Zingg, [@B90]; Adan and Burbach, [@B2]; Lipkin et al., [@B58]; Burbach et al., [@B14]; Lopes da Silva and Burbach, [@B59]; Chu and Zingg, [@B18]; Dellovade et al., [@B23]; Stedronsky et al., [@B109]; Koohi et al., [@B49]; Wang et al., [@B125]).

Although the OT ERE has been studied for its ability to interact with a number of different receptors, differences in regulation elicited by various ligands has not been well-studied. Koohi et al. ([@B49]) compared E2 to Tamoxifen, raloxifene, and ICI 180,780 effects at the bovine OT promoter in the presence of ERalpha. They found that the profile of all of the "antagonists" was in keeping with their activity through alternate pathways. That is, when used alone they elicited activity at the OT response element but not at an individual vitellogenin ERE, a site which is very close to being a consensus sequence. With respect to 3β-Diol effects on OT expression, we have recently found that ERalpha and beta are differentially recruited to the OT promoter. Furthermore, this recruitment is a function of receptor ligand (Figure [2](#F2){ref-type="fig"}). A hypothalamic cell line derived from mice (mHypoE-38; Mayer et al., [@B66]) was used for ChIP analysis. By 30 min, 3β-Diol stimulated ERbeta occupancy to fourfold that of vehicle. At 60 min, both ligands reduced promoter occupancy by both receptors (Figure [2](#F2){ref-type="fig"}; unpublished data). Thus, 3β-Diol and E2 differentially regulate OT promoter occupancy by ERalpha and ERbeta in a time dependent manner.

![**E2 and 3β-Diol lead to different patterns of promoter occupancy by ERα and ERβ**. mHypoE-38 cells were treated with E2 (10^−7^ M) or 3β-Diol (10^−7^ M) for 30 or 60 min. Anti-ERα or anti-ERβ antiserum was used for chromatin immuno-precipitation followed by quantitative PCR of the OT promoter. *n* = 4; Bars represent the mean ± SEM and are presented as the fold difference of vehicle. \*\*, *p* \< 0.01, \*\*\*, *p* \< 0.001.](fendo-02-00065-g002){#F2}

Taken together, the available molecular data underscore the complexity of OT regulation. An important point to be taken is that the species differences are so striking that generalizations with respect to regulation of this stress regulatory neuropeptide can only be made with caution.

Significance
============

Clinical and preclinical studies of MDD provide evidence linking the reported dysregulation of the HPA axis and depressive neuropathology. This dysregulation is characterized by increased cortisol secretory responses, enlarged adrenal gland volume (Rubin et al., [@B96], [@B95]) and elevated CRH in cerebrospinal fluid (Nemeroff et al., [@B73]) in depressed patients. Furthermore, 20--40% of depressed patients are dexamethasone (DEX) non-suppressors (i.e., DEX suppresses ACTH and cortisol to a much smaller extent than healthy controls) and the inability of DEX to suppress cortisol release following a CRH stimulation can distinguish greater than 90% of depressed patients from non-depressed controls (Heuser et al., [@B38]). Neurobiological evidence for HPA involvement in MDD comes from postmortem studies showing that the PVN of depressed patients contains four times the number of CRH expressing cells (Raadsheer et al., [@B87]). Increases in the number of oxytocin and AVP-ir neurons in the PVN have been reported as well (Raadsheer et al., [@B88]; Purba et al., [@B86]). Of interest, plasma vasopressin levels have been shown to be elevated in MDD patients (Van Londen et al., [@B116]). Similarly, nocturnal plasma OT levels have recently been reported to be elevated in individuals with major depression (Parker et al., [@B83]), although earlier studies show a negative correlation between oxytocin levels and depressive symptoms (Scantamburlo et al., [@B98]). Pulsatile patterns of oxytocin release have also been reported to be more variable in depressed women (Cyranowski et al., [@B22]). Consequently, estrogen and androgen signaling in brain may influence the regulation of HPA axis function and may impact the dysregulation of the HPA axis seen in patients with affective disorders thus underlying susceptibility to affective disorders. Further work is required to identify estrogen receptor regulated genes that may be targets for future pharmacological intervention.
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